Evidence map›Paper›PMID 33420393›Full record

ArticleBone marrow transplantation2021

Reduced leukemia relapse through cytomegalovirus reactivation in killer cell immunoglobulin-like receptor-ligand-mismatched cord blood transplantation.

Hisayuki Yokoyama, Junya Kanda, Yuta Kawahara, Naoyuki Uchida, Masatsugu Tanaka, Satoshi Takahashi, Makoto Onizuka, Yuma Noguchi, Yukiyasu Ozawa, Yuna Katsuoka and 8 more

Abstract read
PubMed Publisher
In one paragraph

Article in Bone marrow transplantation, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.8field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 15 institutions in 1 country.

Hisayuki YokoyamaDepartment of Hematology and Rheumatology, Tohoku University Graduate School of Medicine, Sendai, Japan. hisayuki.yokoyama.a1@tohoku.ac.jp.ORCID http://orcid.org/0000-0001-7658-0687
Junya KandaDepartment of Hematology and Oncology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.ORCID http://orcid.org/0000-0002-6704-3633
Yuta KawaharaDepartment of Pediatrics, Jichi Medical University School of Medicine, Shimotsuke, Japan.ORCID http://orcid.org/0000-0002-0192-7233
Naoyuki UchidaDepartment of Hematology, Federation of National Public Service Personnel Mutual Aid Associations Toranomon Hospital, Tokyo, Japan.ORCID http://orcid.org/0000-0001-5952-5926
Masatsugu TanakaDepartment of Hematology, Kanagawa Cancer Center, Yokohama, Japan.
Satoshi TakahashiDivision of Molecular Therapy, The Advanced Clinical Research Center, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.
Makoto OnizukaDepartment of Hematology/Oncology, Tokai University School of Medicine, Isehara, Japan.
Yuma NoguchiHematology Division, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, Tokyo, Japan.
Yukiyasu OzawaDepartment of Hematology, Japanese Red Cross Nagoya First Hospital, Nagoya, Japan.
Yuna KatsuokaDepartment of Hematology, National Hospital Organization Sendai Medical Center, Sendai, Japan.
Shuichi OtaDepartment of Hematology, Sapporo Hokuyu Hospital, Sapporo, Japan.ORCID http://orcid.org/0000-0002-3631-244X
Takanori OhtaDepartment of Hematology, Kitakyushu City Hospital Organization, Kitakyushu Municipal Medical Center, Kitakyushu, Japan.
Takafumi KimuraPreparation Department, Japanese Red Cross Kinki Block Blood Center, Ibaraki, Japan.
Yoshinobu KandaDivision of Hematology, Jichi Medical University, Shimotsuke, Japan.ORCID http://orcid.org/0000-0002-4866-9307
Tatsuo IchinoheDepartment of Hematology and Oncology, Research Institute for Radiation Biology and Medicine, Hiroshima University, Hiroshima, Japan.
Yoshiko AtsutaJapanese Data Center for Hematopoietic Cell Transplantation, Nagoya, Japan.ORCID http://orcid.org/0000-0003-4404-2870
Hideki NakasoneDivision of Hematology, Jichi Medical University Saitama Medical Center, Saitama, Japan.ORCID http://orcid.org/0000-0001-5812-9315
Satoko MorishimaDivision of Endocrinology, Diabetes and Metabolism, Hematology, Rheumatology (Second Department of Internal Medicine), Graduate School of Medicine, University of the Ryukyus, Nishihara, Japan.ORCID http://orcid.org/0000-0002-7391-4271
Jichi Medical University · JPHiroshima University · JPJapanese Red Cross Society, Japan · JPKanagawa Prefectural Hospital Organization · JPKitakyushu Municipal Medical Center · JPKyoto University · JPSapporo Hokuyu Hospital · JPSendai Medical Center · JPThe Japanese Data Center for Hematopoietic Cell Transplantation · JPThe University of Tokyo · JPTohoku University · JPTokai University · JPTokyo Metropolitan Komagome Hospital · JPToranomon Hospital · JPUniversity of the Ryukyus · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cytomegalovirus (CMV) reactivation in cord blood transplantation (CBT) may result in the proliferation and maturation of natural killer (NK) cells. Similarly, a mismatch of the killer cell immunoglobulin-like receptor (KIR)-ligand induces NK cell activation. Therefore, if CMV reactivation occurs in the presence of KIR-ligand mismatch, it might improve CBT outcomes. We assessed the difference in the effect of CMV reactivation in the presence of KIR-ligand mismatch on disease relapse in the graft-versus-host direction. A total of 2840 patients with acute myeloid leukemia, acute lymphoblastic leukemia, myelodysplastic syndrome, and chronic myeloid leukemia were analyzed. Among those with a HLA-Bw4/A3/A11 (KIR3DL-ligand) mismatch, CMV reactivation up to 100 days following CBT had a favorable impact on relapse (18.9% vs. 32.9%, P = 0.0149). However, this effect was not observed in cases without the KIR3DL-ligand mismatch or in those with or without a HLA-C1/C2 (KIR2DL-ligand) mismatch. The multivariate analysis suggested that CMV reactivation had a favorable effect on relapse only in cases with a KIR3DL-ligand mismatch (hazard ratio 0.54, P = 0.032). Moreover, the interaction effect between CMV reactivation and KIR3DL-ligand mismatch on relapse was significant (P = 0.039). Thus, our study reveals the association between KIR-ligand mismatches and CMV reactivation, which will enhance CBT outcomes.

Indexed as

Cord Blood Stem Cell TransplantationGraft vs Host DiseaseHematopoietic Stem Cell TransplantationCytomegalovirusHumansLigandsReceptors, KIRRecurrenceLigandsReceptors, KIR

Identifiers

PMID33420393
OpenAlexW3120528880

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.